Contrary to the previous belief that insulin does not act in the brain, studies in the last three decades have demonstrated important roles of insulin and insulin signal transduction in various functions of the central nervous system. Deregulated brain insulin signaling and its role in molecular pathogenesis have recently been reported in Alzheimer's disease (AD). In this article, we review the roles of brain insulin signaling in memory and cognition, the metabolism of amyloid β precursor protein, and tau phosphorylation. We further discuss defi ciencies of brain insulin signaling and glucose metabolism, their roles in the development of AD, and recent studies that target the brain insulin signaling pathway for the treatment of AD. It is clear now that deregulation of brain insulin signaling plays an important role in the development of sporadic AD. The brain insulin signaling pathway also offers a promising therapeutic target for treating AD and probably other neurodegenerative disorders.
Introduction
Alzheimer's disease (AD) is the most common form of dementia, accounting for an estimated 60% to 80% of all cases [1] . It is characterized by progressive loss of memory and other cognitive functions. It is genetically classified into late-onset sporadic AD (SAD) and earlyonset familial AD. Familial AD constitutes <5% of all AD cases and is caused by mutations in genes for amyloid-β
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Brain Insulin Signaling
The brain was considered to be insulin-independent until the discovery of the widespread distribution of IRs in the brain [20] [21] [22] [23] . IRs are located on both astrocytes and neurons, and have the highest density in the olfactory bulb, cerebral cortex, hippocampus, hypothalamus, cerebellum, and choroid plexus [20, [24] [25] [26] [27] .
Most of the insulin in the brain may come from the periphery. Insulin can cross the blood-brain barrier by a saturable, receptor-mediated transport mechanism [28] .
The specific receptor/transporter has not been identified,
but the transport appears to saturate at euglycemic concentrations of insulin [28] . Many factors, such as fasting, obesity, aging, and dexamethasone treatment, can lead to a decreased transport of insulin into the central nervous system (CNS) [29, 30] . Whether insulin can also be produced in the mammalian brain is still under debate. Direct evidence of a central source of insulin in the brain is still lacking. Havrankova et al. [21] identified insulin in wholebrain extracts, and its concentration differed in extracts from various regions of the brain. Thereafter, more efforts have been made to confi rm the local synthesis of insulin. A series of studies have found preproinsulin mRNA in animal brain [31, 32] . The release of insulin [33] , and the presence of insulin mRNA [34] and insulin-like immunoreactivity [35] , have also been detected in cultured neurons, suggesting the neuronal synthesis of insulin. Moreover, insulin is proposed to be only produced by a subset of neurons like pyramidal neurons in the hippocampus, prefrontal cortex, entorhinal cortex, and olfactory bulb, but not by glial cells [33, 36, 37] .
IRs have been shown to be highly enriched in postsynaptic densities in rat cerebral cortex, hippocampus, and cerebellum, where IRS is also highly enriched [38] .
In addition, IRs co-localize with IRS in cerebellar and hippocampal neurons. Another study also showed that IRS-1 mRNA is co-localized with IR mRNA in neuronal cell bodies of the hippocampus and olfactory bulb [39] . The expression of other downstream effectors such as PI3K, AKT, and glycogen synthase kinase-3 (GSK-3) also reveals a pattern somewhat overlapping that of IRs in the brain [40] [41] [42] .
All this evidence suggests the presence of active insulin signal transduction in brain regions closely associated with cognition and the importance of insulin signaling for synaptic function. in AD; they are characterized by reduced amounts of insulin in the brain [68] , reduced levels of IR-binding [69] [70] [71] , and decreased responsiveness of downstream effectors to the activation of IRs [72, 73] . Brain regions with the most abundant expression of IRs such as the hippocampus, the temporal lobe, and the cerebral cortex, are the most vulnerable targets of AD [38] . The reduced insulin mRNA levels and insulin-binding in the frontal cortex and hippocampus are associated with the Braak stage of AD pathology [69, 70] .
However, Frolich et al. reported increased IR-binding in the occipital cortex that is not associated with cognition [74] .
Insulin signaling defects may account for many of the clinical manifestations of AD, and they actually begin early and progress with the development of the disease.
Experimental animals, in which the brain insulin signaling pathway is impaired, exhibit cognitive impairment and neurodegeneration with features in common with AD [64, 75] .
It is now proposed that brain insulin signaling defects can lead to the overexpression of APP, accumulation of Aβ, hyperphosphorylation of tau, reduction in glucose metabolism and energy utilization, promotion of oxidative stress and neuroinflammation, synaptic failure, and as a result, a decline in cognition and the development of AD [14] .
Small clinical trials have shown potential benefi cial effects of therapeutics targeting the insulin signaling pathway in treating AD [76] [77] [78] [79] , though more larger-scale clinical trials with longer durations are still needed to confirm the effectiveness and safety of these drugs.
Brain Insulin Signaling and Cognition
The hippocampus and cortex, structures responsible for memory and other cognitive functions, display highly enriched distributions of IRs, IRS, and other downstream effectors [38] [39] [40] [41] [42] , suggesting that brain insulin signaling might be involved in memory and cognition.
Intracerebroventricular or intrahippocampal administration of insulin improves spatial memory consolidation and retrieval in the Morris water maze test [80, 81] , and enhances performance in the passive-avoidance task in rats [82, 83] .
Selective blockade of endogenous intrahippocampal insulin signaling impairs memory performance [84] . Besides, chronic intranasal insulin treatment enhances short-term and longterm object-recognition memory in mice [85] and slows down the impairment of object recognition memory in diabetic mice [86] . On the other hand, short-and long-term memory formation induce signifi cant up-regulation of IR expression in the hippocampus [87, 88] . Changes in downstream molecules, such as upregulation of IRS-1 and Akt in synaptic membrane, translocation of Shc protein to synaptic membrane, and activation of MAPK, also occur after longterm memory formation [88] , suggesting the involvement of insulin signaling in spatial memory processing. This is also supported by clinical trials: intravenous insulin infusion using the hyperinsulinemic-euglycemic clamp method improves memory performance and attention in humans [89, 90] ; intranasal insulin treatment improves cognition and memory in healthy people and in people with mild cognitive impairment (MCI) or AD [76, 91, 92] .
Inhibition of brain insulin signaling, on the other hand, results in the impairment of memory and cognition. We have found that intracerebroventricular administration of streptozotocin in mice impairs brain insulin signaling, leading to reduced long-term spatial memory and shortterm object-recognition memory [63] , and further exacerbates the memory impairment in 3×Tg-AD mice [93] . However, mice with brain/neuron-specifi c IR knockout display normal spatial learning in the Morris water maze task [94] . This might be because an early lack of IRs can be compensated over time by other pathways.
The mechanisms underlying the effects of insulin on cognition are still not clear. One possible mechanism is its regulatory effect on glucose metabolism and energy utilization, which will be discussed in detail later in this review. The brain insulin signaling pathway has also been implicated in cortical and hippocampal synaptic plasticity, thus affecting memory and learning. Studies have shown that insulin is able to induce both long-term potentiation and long-term depression (LTD) in a PI3K-dependent manner in the CA1 region of rat hippocampal slices [95, 96] , through the modulation of α-amino-3-hydroxy-
aspartic acid (NMDA), and γ-aminobutyric acid (GABA) receptors [97] [98] [99] . Insulin accelerates the endocytosis of AMPA receptors containing the glutamate GluR2 subunit, thus decreasing its numbers in the plasma membrane, and resulting in LTD of AMPA receptor-mediated synaptic transmission in hippocampal CA1 neurons [97] . Insulin is also reported to promote the rapid delivery of NMDA receptors to the cell surface by exocytosis [100] , and influence their activity. It is reported that insulin can cause transient phosphorylation of NR2A and NR2B subunits of NMDA receptors at tyrosine residues in hippocampal slices, and this is responsible for insulin-induced potentiation [98] .
All this evidence suggests that the beneficial effects of insulin on memory result, at least partially, from the modulation of glutaminergic neurotransmission. In addition,
GABAergic neurotransmission plays a role, as insulin increases the expression of GABA receptors on the postsynaptic and dendritic membranes of neurons and the number of functional postsynaptic GABA receptors, thereby increasing the amplitude of miniature inhibitory postsynaptic currents mediated by GABA receptors [99] .
Furthermore, the production of acetylcholine [101] and uptake of norepinephrine [102] that influence cognitive function are also regulated by insulin.
Brain Insulin Signaling and APP Metabolism
Aβ peptides generated by the proteolytic processing of APP Insulin promotes APP metabolism and increases the rate of secretion of APP in a PI3K-dependent manner [60] .
It has been shown that insulin stimulation accelerates APP/Aβ trafficking from the trans-Golgi network, a major cellular site for Aβ generation, to the plasma membrane, and reduces the intracellular accumulation of Aβ [61, 62] . This molecular mechanism is further supported by clinical trials showing that insulin infusion increases the Aβ 42 level in the cerebrospinal fluid (CSF) of nondemented humans [103, 104] .
I n s u l i n m a y a l s o m o d u l a t e t h e e x t r a c e l l u l a r degradation of Aβ via insulin degrading enzyme (IDE), a metalloproteinase that catabolizes insulin. IDE is highly expressed in the brain as well as in liver, kidney and muscle tissue, and plays a crucial role in Aβ clearance by both degradation and oligomerization [105] [106] [107] . When the IDE gene is knocked out in the mouse brain, the Aβ level is elevated [108] . In addition to Aβ, IDE also degrades a variety of peptides including insulin itself. Therefore, by competing with Aβ for binding, insulin inhibits Aβ degradation and increases its extracellular concentration. On the other hand, the expression of IDE in the brain can be affected by insulin. Studies have shown that insulin increases the IDE protein levels via activation of PI3K [109] . This is also supported by the finding that deficient insulin signaling is correlated with reduced IDE in the AD brain [109] . The Aβ-degrading activity of IDE, as well as its mRNA and protein levels, are decreased in the AD brain, and these decreases correlate negatively with the Aβ level [110] [111] [112] . Induction of insulin resistance in Tg2576 mice reduces the amount and activity of IDE and, as a result, increases Aβ levels in the hippocampus and cerebral cortex [109] .
On the other hand, Aβ is intimately associated with defective insulin signaling. Treatment of cultured hippocampal neurons with Aβ oligomers and intracerebroventricular injection of Aβ oligomers in monkeys both increase IRS1 phosphorylation at multiple serine residues in cells and monkey brains [113] . Aβ oligomers can also bind to hippocampal neurons and trigger the removal of IRs from the plasma membrane, resulting in reduction of the number of surface IRs and the responsiveness to insulin [114] . This has also been verified in the AD brain,
where IRs are concentrated inside the intracellular compartment, unlike its distribution throughout the neuronal soma and dendrites in control brains [68] . This Aβ oligomerinduced loss of surface IRs and the subsequent loss of synaptic spines can be completely prevented by insulin treatment [114, 115] .
Brain Insulin Signaling and Tau Phosphorylation
Abnormally-hyperphosphorylated tau is the principal component of paired helical filaments in the neurofibrillary lesions associated with AD [116] . Abnormal hyperphosphorylation reduces the affinity of tau to microtubules and is crucial for neurodegeneration in AD and other tauopathies [117, 118] . Negative regulation of tau phosphorylation by insulin has been reported. Treatment of cultured human neuronal NT2N cells with insulin results in decreased tau phosphorylation [119] . In contrast, depletion of IRs in the brain, as seen in brain/neuron-specific IRknockout mice, results in increased tau phosphorylation [120] .
In IRS2-knockout mice, a type 2 diabetes model, accumulation of hyperphosphorylated tau is detectable in the hippocampus [94] . Inhibition of brain insulin signaling by intracerebroventricular administration of streptozotocin also induces hyperphosphorylation of tau at multiple sites and reduces its ability to bind to microtubules in rodents [63, 64] .
This treatment also exacerbates tau pathology in 3×Tg-AD mice [93] . These fi ndings are consistent with the negative regulation of GSK-3β activity by insulin signaling, because GSK-3β is the major kinase for tau phosphorylation in the brain [121] . However, a transient increase in tau phosphorylation also occurs in SH-SY5Y cells and in primary cortical neurons after insulin treatment [122, 123] .
Therefore, the regulation of tau phosphorylation by insulin signaling may be dynamic and time-dependent.
We previously showed that altered tau O-GlcNAcylation, an O-linked post-translational modification of nucleocytoplasmic proteins by the monosaccharide β-Nacetylglucosamine (GlcNAc), links the impairment of brain glucose metabolism to tau hyperphosphorylation [124] [125] [126] .
In the AD brain, impaired glucose metabolism may lead to the down-regulation of O-GlcNAcylation that, in turn, facilitates abnormal hyperphosphorylation of tau and neurodegeneration [127, 128] (Fig. 1) . Decreased glucose uptake/metabolism in the brain partially results from impaired brain insulin signaling, leading to decreased tau O-GlcNAcylation and increased tau phosphorylation, which is also evidenced by animal studies [64] . On the other hand, insulin might increase tau expression via accelerating protein synthesis through the PI3K-mTOR pathway [129] .
Defi ciency of Brain Insulin Signaling and Glucose
Metabolism in AD
Accumulating evidence supports the hypothesis that AD is a metabolic disease with impaired brain insulin signaling, leading to neurodegeneration. Deficient insulin signaling begins early and progresses with the development of the disease [69, 70] . The level of insulin in the CSF and/ or the CSF/plasma insulin ratio is decreased in the AD brain [68] . Increasing Braak stages of AD neuropathology are associated with progressively reduced mRNA levels of insulin/IGF and their receptors [69, 70] . We and others have demonstrated reduced protein levels and activity of downstream effectors of insulin signaling in the AD brain, including IRs, IRS, PI3K, and AKT [68, 71, 73] , as well as reduced responsiveness of the insulin signaling pathway to insulin/IGF stimulation [72] . All this evidence indicates that insulin signaling is impaired in the AD brain and may play a critical role in the pathogenesis and progression of the disease.
Impairment of cerebral glucose metabolism occurs at the early stage of AD and deteriorates further with progression of the disease [3] [4] [5] [6] [7] . However, the underlying mechanism is still unclear. Neurons are unable to synthesize or store glucose, and thus they are fully dependent on glucose transport across the blood-brain barrier, which is facilitated by glucose transporters (GLUTs).
In mammalian brain, GLUT1 and GLUT3 are predominant in glucose transport into the neuron [130] . GLUT1 is highly expressed in endothelial cells of the blood-brain barrier and is responsible for transporting glucose from blood into the extracellular space of the brain [131] . GLUT3 is the major neuronal GLUT and helps transport glucose from the extracellular space into neurons [132] . Decreased GLUT1 and GLUT3 have been reported in the AD brain [65] [66] [67] . We further demonstrated that the decreases in GLUT1 and GLUT3 levels correlate with the decrease in O-GlcNAcylation and hyperphosphorylation of tau in the AD brain [66, 67] .
Because GLUT1 and GLUT3 are insulin-insensitive, brain glucose metabolism was previously viewed as being independent of insulin. However, these glucose transporters do appear to be regulated by insulin [133, 134] .
Furthermore, the existence of GLUT4, an insulin-sensitive GLUT, in brain regions involved in memory and cognition such as the hippocampus and temporal cortex [135] adds the possibility that insulin might also influence memory in part through GLUT4-mediated glucose uptake. A fl udeoxyglucose F18-positron emission tomography study revealed a regional association between a lower cerebral glucose metabolic rate and greater insulin resistance [136] .
When insulin signaling is inhibited in the human brain, hippocampal energy metabolism is significantly reduced during cognitive activity [137] . Intracerebroventricular injection of insulin stimulates the translocation of GLUT4 to the plasma membrane in rat hippocampus in a time-and PI3K-dependent manner, providing a mechanism through which neurons rapidly increase glucose utilization during increases in hippocampus-associated activities such as learning and memory [138] . Collectively, brain glucose metabolism is impaired in the AD brain; this is associated with reduced GLUT1 and GLUT3 levels and impaired brain insulin signaling (Fig. 1 ).
Brain Insulin Signaling as a Therapeutic Target for AD
As reviewed above, defective insulin signaling is closely associated with AD pathology and memory impairment.
Therapeutics aimed at enhancing insulin signaling in the brain are expected to be promising in treating AD.
Approaches using insulin, glucagon-like peptide-1 [139] . Several studies have shown that both acute and chronic intranasal insulin treatment (160 IU/day) enhance memory and mood in healthy adults [58, 59, 140, 141] .
Acute intranasal administration of insulin at various doses (10, 20, and 40 IU) also improves declarative memory in adults with MCI and AD. In contrast, 60 IU of insulin does not facilitate memory [78] . Interestingly, the benefi cial effects of insulin differ according to the apolipoprotein E (APOE) genotype, a genetic risk factor for sporadic AD. Only APOE-ε4-negative MCI or AD patients show improved declarative memory [79] . In addition, chronic intranasal insulin (40 IU/day) of participants with early AD improves declarative memory and attention and induces an increased plasma Aβ 40 /Aβ 42 ratio following 21 days of treatment [77] . A follow-up study of 4 months of intranasal insulin treatment also showed improved delayed memory in MCI and AD patients, and the changes in CSF Aβ 42 and tau/Aβ 42 ratios are associated with cognitive and functional changes [76] . All these studies have provided promising evidence that intranasal insulin may benefi t MCI and AD patients. However, larger, longer, and multi-center clinical trials are still needed to further substantiate the beneficial effects of insulin on cognition and also evaluate the potential side-effects.
PPAR-γ agonists are also attractive candidates for treating defective insulin signaling. However, clinical trials using agonists such as rosiglitazone and pioglitazone fail to show consistent beneficial results in AD patients [142] [143] [144] .
In addition, safety concerns about the effects of PPAR-γ agonists on cardiovascular function and heart failure in diabetic patients have restricted its clinical use. It will be worth performing clinical trials using intranasal administration of PPAR-γ agonists in the future.
Other drugs like GLP-1 agonists and metformin have been shown to ameliorate multiple pathological changes linked to AD in cell culture and animal models [145, 146] . More studies and clinical trials are needed to determine the effi cacy of these drugs in treating AD. 
